An Open-Label Phase II Study in Anti-GBM Disease (Goodpasture's Disease) With Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS --GOOD-IDES

Trial Profile

An Open-Label Phase II Study in Anti-GBM Disease (Goodpasture's Disease) With Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS --GOOD-IDES

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs IdeS (Primary)
  • Indications Anti glomerular basement membrane disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms GOOD-IDES
  • Most Recent Events

    • 14 Nov 2017 According to a Hansa Medical AB media release, till date 5 patients had been included in this study and limited follow-up data from three of these five patients is now available.
    • 20 Jun 2017 According to a Hansa Medical AB media release, the first patient is treated in this study.
    • 15 May 2017 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top